TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
33 hedge funds and large institutions have $114M invested in TCR2 Therapeutics Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
38% more funds holding
Funds holding: 24 → 33 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $136M → $114M (-$22.5M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.68M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$643K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$389K |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$257K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.58M |
| 2 |
Goldman Sachs
New York
|
-$984K |
| 3 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$694K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$458K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$436K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Legal & General Group
London,
United Kingdom
| $8K | +$8.7K | +545 | New |
|
27
Citigroup
New York
| $7K | -$28.5K | -1,787 | -80% |
|
|
CCA
28
Catalyst Capital Advisors
Huntington,
New York
| $7K | – | – | – |
|
29
Bank of Montreal
Toronto,
Ontario, Canada
| $2K | +$2.44K | +153 | New |
|
|
AIP
30
Ameritas Investment Partners
Lincoln,
Nebraska
| $2K | +$2.5K | +157 | New |
|
31
BNP Paribas Financial Markets
Paris,
France
| $1.12K | +$1.24K | +78 | New |
|
32
Morgan Stanley
New York
| $1K | -$13.1K | -819 | -94% |
|
|
33
Goldman Sachs
New York
| – | -$984K | -56,443 | Closed |
|
|
DIM
34
DC Investments Management
Mclean,
Virginia
| – | -$694K | -39,814 | Closed |
|
|
BCM
35
BlueCrest Capital Management
St Helier,
Jersey
| – | -$458K | -26,255 | Closed |
|
|
36
Norges Bank
Oslo,
Norway
| – | -$436K | -25,000 | Closed |
|
|
LCM
37
Laurion Capital Management
New York
| – | -$417K | -23,900 | Closed |
|
|
OAM
38
Oxford Asset Management
Oxford,
United Kingdom
| – | -$301K | -17,296 | Closed |
|
39
Wells Fargo
San Francisco,
California
| – | +$223 | +14 | New |
|
TCRR Hedge Fund Activity: Q2 2019 in Review
33 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2019, worth a combined $114M — down 17% from $136M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TCRR positions and 6 closed out — a net gain of 9 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $1.68M. The largest seller was Millennium Management, cutting an estimated $1.58M.
- 33 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2019, up from 24 in Q1 2019.
- Funds reported $114M of TCR2 Therapeutics Inc. Common Stock stock for Q2 2019, down 17% quarter-over-quarter.
- 15 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2019 and 6 closed out, a net change of +9 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q2 2019 was BlackRock, an estimated $1.68M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2019 was Millennium Management, an estimated $1.58M sold.
Based on aggregated 13F filings for Q2 2019.